Scientists at the National Institutes of Health’s new intramural research effort, the Center for Alzheimer's and Related Dementias (CARD), have purchased Oxford Nanopore’s PromethION de...

Today the Court of Appeals for the Federal Circuit issued a unanimous Precedential Opinion and Judgment affirming the jury’s March 2020 verdict in the PacBio v. Oxford Nanopore case, that...

Oxford Nanopore has released new protocols enabling the rapid, cost effective sequencing of SARS-CoV-2 — the virus that causes COVID-19. Research teams are able to access sequencing techn...

Please click here for the full text of this announcement.

ORG.one is a pilot-stage project designed to support faster, more localised sequencing of critically endangered species, by enabling biologists to rapidly sequence those species close to ...

With just one week to go until London Calling 2021 online (19th-21st May), we are thrilled to share details of further additions to our speaker line-up. For more details on the talks anno...

Oxford Nanopore has announced that Tim Cowper is taking the role of Chief Financial Officer, and Jordan Herman has joined as General Counsel. “We’re delighted to announce that Tim will...

Please click here for the full text of this announcement.

Results from developers on human samples — MinION (left) and PromethION (right) The Ultra-Long DNA Sequencing Kit, which has enabled read lengths of up to 4.2 Mb and maximises the quanti...

Kahlil Corazo is an entrepreneur and project manager from the Philippines who initiated and led Project Accessible Genomics, a low-cost genomic sequencing operation that aims to bring pat...

A new nanopore sequencing kit is now being tested by a number of developers in the nanopore user community.  The kit features a modified enzyme, tweaked run conditions and a further impro...

Due to current COVID-19 restrictions and following on from the success of last year’s virtual London Calling conference, the upcoming London Calling 2021 is also going ahead online. Ki...

Mobile COVID-19 testing laboratories containing Oxford Nanopore’s LamPORE test are now being deployed in a pilot programme, to support testing efforts, including in remote locations. The...

Oxford Nanopore Technologies and NVIDIA are collaborating this year to integrate the NVIDIA DGX Station A100 into Oxford Nanopore’s ultra-high throughput sequencing system, PromethION. P...

Dear all, As each year draws to an end, we reflect on its highlights. You can read our 2019 and 2018 blogs here. But 2020 was a year like no other; it's hard to think of the following as...

Oxford, 21st December 2020. A study of more than 23,000 samples carried out by teams across the UK shows Oxford Nanopore’s COVID-19 test, LamPORE, is highly accurate for the detection of...

Oxford Nanopore’s rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities. Oxford Nanopore Technologies Limited (“Oxford Nanopore”), a leading next gene...

During an update at the 2020 Nanopore Community Meeting, Oxford Nanopore revealed a number of key advances in its sequencing technology. These include the release of new improvements in ...

Two new papers published in Nature Biotech today, from teams at the University of Nottingham and Johns Hopkins University, demonstrate the use of real-time nanopore sequencing and adaptiv...

Today marks the release of the MinKNOW App for iOS and Android devices, now available to download from the Apple Store and Google Play. MinKNOW is the operating software that drives nano...

Somatic mutations are the driving force behind cancer development, and structural variations (SVs) are more and more being recognised as an important class of these mutations. The detecti...

Adam Ewing leads the Translational Bioinformatics Group at the Mater Research Institute - University of Queensland in Australia, where he works to develop methods and software for anal...

The significance of structural variation in human genomics is becoming increasingly established in many fields, from cancer to neurology and the mechanisms of rare disease. With research ...